LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NYSE: PBYI), a development stage
biopharmaceutical company, today announced that it is commencing an
underwritten registered public offering of 1,000,000 shares of its
common stock. Puma Biotechnology intends to grant the underwriters a
30-day option to purchase up to an additional 150,000 shares of its
common stock. All of the shares are being offered by Puma Biotechnology.
BofA Merrill Lynch and J.P. Morgan are acting as lead book-running
managers and Citigroup is acting as joint book-running manager for the
offering. Leerink Partners LLC and Cowen and Company, LLC are acting as
co-managers for the offering. The offering is subject to market and
other conditions and there can be no assurances as to whether or when
the offering may be completed, or as to the actual size or terms of the
offering.
The offering is being made pursuant to an automatically effective shelf
registration statement filed with the Securities and Exchange Commission
on January 20, 2015. A preliminary prospectus supplement describing the
terms of the offering will be filed with the Securities and Exchange
Commission and will form a part of the effective registration statement.
Copies of the preliminary prospectus supplement and accompanying
prospectus relating to the offering may be obtained, when available, by
contacting BofA Merrill Lynch, 222 Broadway, New York, NY 10038, Attn:
Prospectus Department, email: [email protected];
J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions,
1155 Long Island Avenue, Edgewood, New York 11717, Phone: (866)
803-9204; or Citigroup, c/o Broadridge Financial Solutions, 1155 Long
Island Avenue, Edgewood, NY 11717, phone (800) 831-9146.
This news release shall not constitute an offer to sell or the
solicitation of an offer to buy, nor shall there be any sale of these
securities in any state or other jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or other
jurisdiction.
Contact: